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Summary The prognostic value of c-erbB-2 oncogene expression was studied retrospectively in a consecutive
series of 230 node negative breast cancers, followed-up for at least 7 years after primary treatment. The
expression of c-erbB-2 oncoprotein was determined on formalin-fixed paraffin-embedded tissue, using a
monoclonal anti-c-erbB-2 antibody by the avidin-biotin immunoperoxidase method. Positive immunostaining
was observed in 20.9% of cases, whereas strong diffuse positivity was recorded only in 8.7% of cases.
C-erbB-2 gene product showed no association to T category or nuclear grade. A significant association of
c-erbB-2 expression to prognosis was observed only for cases showing a strong diffuse immunostaining, but
such an association was no longer statistically significant at multivariate analysis adjusting for other prognostic
factors such as T category and nuclear grading. C-erbB-2 expression is of no value to predict the clinical
course of node negative patients in the current practice.
Although node negative (N-) have a better prognosis with
respect to node positive breast cancer patients, still they will
recur in about 25% of cases in the first 10 years after surgery
(Ciatto et al., 1990). No adjuvant postoperative treatment
was recommended in node-negative (N-) patients until a few
years ago (National Institute of Health, 1986), but recently
many studies have been aimed at the identification of prog-
nostic indicators allowing to select high-risk node-negative
patients in whom adjuvant treatment may be worthwhile and
cost-effective.
Proto-oncogenes have been studied with this purpose, and
recently the amplification and overexpression of c-erbB-2
oncogenes have been demonstrated to be strongly associated
with breast cancer aggressiveness in node-positive subjects
(Slamon et al., 1987). Further studies on this subject reported
controversial results either demonstrating (Varley et al., 1987;
Cline et al., 1987; Berger et al., 1988; Wright et al., 1989;
Tandon et al., 1989; Lovekin et al., 1989; Paik et al., 1990;
Querzoli et al., 1990) or denying (Van de Vijer et al., 1988;
Barnes et al., 1988; Ali et al., 1988; Gusterson et al., 1988)
the presence of such a prognostic association. No significant
association of c-erbB-2 amplification and expression with
prognosis has been observed for node-negative subjects in a
limited number of studies (Barnes et al., 1988; Tandon et al.,
1989; Paik et al., 1990; Gullick et al., 1991; Clark &
McGuire, 1991).
The c-erbB-2 oncogene encodes a 185-190 kilodalton
transmembrane glycoprotein which has considerable homo-
logy with the epidermal growth factor receptor (Schechter et
al., 1984; Coussens et al., 1985), and a close association has
been demonstrated between gene amplification, as determined
by Southern blotting, and protein expression, as determined
immunohistochemically (Berger et al., 1988). In the present
study c-erbB-2 expression has been retrospectively inves-
tigated by an immunohistochemical method in a consecutive
series of node negative breast cancer cases, to determine its
prognostic value and its reliability as a discriminant factor
for adjuvant treatment in these patients.
Material and methods
The present study considers 230 cases of node-negative
infiltrating breast cancer, consecutively diagnosed at the Cen-
tro per lo Studio e la Prevenzione Oncologica of Florence
and undergoing surgical treatment from November 1978 to
December .1984.
Data available for each case were: patient's age, tumour
size, T and N pathological category (UICC, 1987), nuclear
grade, type and date of primary treatment, date of first
recurrence and final status. Pathological nodal status had
been assessed on an average of 21 examined nodes. Nuclear
grade had been determined according to the criteria proposed
by Black and Speer (1957) and modified by Fisher et al.
(1980). Primary treatment was radical or modified radical
mastectomy or quadrantectomy plus axillary dissection plus
breasts irradiation, the latter being performed in most Tl
cases. No postoperative adjuvant treatment was performed.
Patients were actively followed up and final status was
assessed in December 1991 when no patient had been lost to
follow up.
Routinely formalin-fixed, paraffin embedded specimens
were obtained from the archives of the Institute ofPathology
of Florence University. Sections were cut at 5 jsm, mounted
on poly-L-lysine coated glass slides and air dried overnight at
37'C. Sections were deparaffinised through xylene and graded
alcohols and treated for 10' at room temperature with
absolute methanol and 0.5% hydrogen peroxide to block
endogenous peroxidase activity. Sections were then washed in
phosphate buffered saline (PBS, pH 7.4) and normal horse
serum (Vector Laboratories, Burlingame, Ca, USA) was
applied for 20' to reduce nonspecific antibody binding. C-
erbB-2 protein expression was investigated with the specific
monoclonal mouse antibody mAbl (Triton Diagnostic, Ala-
meda, Ca, USA), an IgGl immunoglobulin which recognises
the external domain of the c-erbB-2 gene product. Sections
were incubated overnight at 4'C with mAbl, at a concentra-
tion of 2.5fLgml-'. For negative controls the primary anti-
body was omitted (Barnes et al., 1988; Lovekin et al., 1989).
On the following day the sections were extensively washed
and incubated with 1:200 diluted biotinylated horse anti-
mouse IgG for 30' at room temperature. Subsequent incuba-
tion with avidib-biotin peroxidase complex (ABC) reagent
(Vector, Burlingame, Ca, USA) was carried out for 30' at
room temperature after extensive washing with PBS. 3,3'
diamino-benzidine-hydrogen peroxide (Sigma, St. Louis, Mo,
USA) was used as chromogen and a light Mayer's hematox-
ylin counterstaining was added.
Cases showing strong focal or diffus tumour cell mem-
brane staining were considered as positive. A few cases show-
ing cytoplasmic cell staining only were regarded as negative.
Results were assessed by one of us (S.B.) according to a
semiquantitative scale based on the percentage of stained
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Figure 1 Strong and diffuse membrane staining of an infiltrating ductal carcinoma ( x 100).
Figure 2 Positive membrane staining of an infiltrating ductal carcinoma (upper left, lower right) compared with unstained normal
ductal and stromal cells.
Table I Distribution of 230 node-negative breast cancer cases by
c-erbB-2 grade and according to age, T category and nuclear
grade
C-erbB-2 grade Total
0 1 2 3
Age: <40 12 1 0 3 16
40-49 40 6 4 2 52
50-59 62 3 4 8 77
>59 68 4 6 7 85
T category: Ti 72 5 2 7 86
T2 98 8 11 11 128
T3 6 0 0 1 7
T4 3 1 0 0 4
Tx 3 0 1 1 5
Nuclear grade: GI 97 5 6 6 114
G2 66 9 5 11 91
G3 19 0 3 3 25
Total 182 14 14 20 230
Table II Distribution of recurrences and cancer deaths (row
percentages are indicated in parentheses) observed according to T
category, nuclear grade and c-erbB-2 grade
Patients Recurrences Cancer
Variable at risk observed (%) (deaths (%)
TI 86 17 (19.8) 11 (12.8)
T2 126 42 (32.8) 34 (26.6)
T3-4 11 7 (63.6) 7 (63.6)
Tx 5 1 (20.0) 0
GI 114 28 (24.6) 20 (17.5)
G2 91 28 (30.8) 23 (25.3)
G3 25 11 (44.0) 9 (36.0)
c-erbB-2 0 182 51 (28.0) 38 (20.9)
1 14 4 (28.6) 3 (21.4)
2 14 4 (28.6) 4 (28.6)
3 20 8 (40.0) 7 (35.0)
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cells - 0 (no stained cells), 1 (1-32%), 2 (33-65%), 3
(>65%) (Figures 1 and 2) - as suggested by Soomro et al.
(1991). Grade attribution was blind of patient's status and
previously assessed nuclear grade. Intraobserver repeatibility
in the attribution of immunostaining degree was determined
at a second reading of the whole series, after random admix-
turing of cases.
The association between T category, nuclear grade and
c-erbB-2 grade was studied by the chi-square test. Statistical
significance level was set at P<0.05. As regards c-erbB-2
expression, in addition to the conventional negative (grade 0)
and positive (grade 1-3) categories, we also compared
strongly positive immunostaining category (grade 3) vs other
grades (0-2).
Univariate analysis of the relation of c-erbB-2 grade, T
category (Tx cases were censored) and nuclear grade to
relapse-free and overall survival was performed. Five-, seven-
and ten-year survivals were determined according to Kaplan
and Meier (1958) and significant differences between survival
curves were checked by the log rank test.
Multivariate analysis of the association of different vari-
able to survival (Cox, 1972) was performed. Variables enter-
ing the proportional hazards regression model were those
which resulted to be associated to survival at univariate
analysis.
negative cases and a significantly worse prognosis was evi-
dent only for subjects showing a strong (grade 3) c-erbB-2
positivity. A Kaplan-Meier plot of survival curves for c-erbB-
2 categories is shown in Figure 3 and Figure 4. Not all
subjects had been followed for 10 years, and the significance
ofdifferences in survival curves observed at 5 years decreased
at longer follow-up as the number of exposed subjects de-
creased.
Table IV shows the results of multivariate analysis of the
association of different variables to disease-free survival. T
category confirmed its independent significant association to
survival after simultaneous adjustment for potential con-
founders, whereas no independent association was observed
for nuclear grade, or c-erbB-2 grade.
Discussion
Many reports on the possible prognostic role of c-erbB-2
expression in node negative patients have been published and
although the results are controversial, the overall impression
which can be drawn is that the prognostic importance of
c-erbB-2 in this subset of patients is at best slight.
Results
Table I shows the distribution of cases according to c-erbB-2
grade, age, T category and nuclear grade. C-erbB-2 expres-
sion was observed in 48 of 230 (20.9%) cases but strong and
diffuse immunostaining was recorded only in 20 cases (8.7%).
No association was observed between c-erbB-2 grade and
age, T category or nuclear grade. Intraobserver agreement on
a two-grade scale (negative/positive) was 100%. Intra-
observer agreement in grade attribution in positive cases was
86% (kappa = 78.59). Disagreement was always within one
grade.
Table II shows the distribution of recurrences and cancer
deaths observed according to T category, nuclear grade, or
c-erbB-2 grade. Disease-free and overall survival rates are
reported in Table III. A significant association to disease-free
and overall survival was observed for T category (TI vs T2 vs
T3-4) whereas nuclear grade (GI vs G2 vs G3) showed a
trend of worse prognosis with increasing grade which did not
reach statistical significance. No significant difference in sur-
vival was evident when comparing c-erbB-2 negative and
positive cases (grade 0, vs grades 1-3). The prognosis of
c-erbB-2 grade 1-2 cases was similar to that of c-erbB-2
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Figure 3 Kaplan-Meier plot
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Table III Disease-free and overall survival rates according to different prognostic variables. Log-rank chi-square (LR) and
survival differences are reported
P value (P) or
Disease free Overall
survival rate survival rate
Syr 7yr 10yr 5yr 7yr 10yr
Variable
Ti 90.6 85.5 77.2 96.4 92.6 83.0
T2 72.1 69.6 65.9 87.2 77.1 70.6
T3-4 36.4 36.4 36.4 63.6 63.6 63.6
(LR) (22.2) (17.8) (13.4) (14.1) (28.0) (21.8) (P) (0.0001) (0.0001) (0.001) (0.0009) (0.0001) (0.0001)
nuclear grade 1 83.1 80.4 73.7 93.8 86.4 79.8
nuclear grade 2 73.9 70.3 67.4 87.5 78.5 69.2
nuclear grade 3 64.0 59.7 53.8 80.0 67.3 61.7
(LR) (5.96) (6.33) (5.34) (5.21) (5.90) (5.68) (P) (0.05) (0.04) (0.07) (0.07) (0.05) (0.06) c-erbB-2 grade 0 79.3 75.8 70.0 90.4 83.3 75.9
c-erbB-2 grade 1-3 70.4 68.2 65.5 87.4 73.6 66.5
(LR) (1.57) (1.15) (0.6) (0.5) (2.25) (1.75) (P) (0.21) (0.28) (0.4) (0.47) (0.13) (0.18)
c-erbB-2 grade 0-2 79.1 75.6 70.0 91.7 82.9 75.1
c-erbB-2 grade 3 60.0 60.0 60.0 70.0 64.2 64.2
(LR) (4.69) (3.2) (2.1) (11.5) (5.8) (3.63) (P) (0.03) (0.07) (0.14) (0.0007) (0.016) (0.056)628 S. BIANCHI et al.
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Figure 4 Kaplan-Meier plot of overall survival curves for c-
erbB-2 subgroups.
C-erbB-2 is expressed relatively infrequently and because
node negative have a better prognosis compared to node
positive patients, relapses and deaths are less frequent. Statis-
tical significance is dependent upon the number of events in
the study and it is to be expected that a large number of
relatively small studies would be affected by such a bias, with
some by chance getting larger effects and so being likely to
show statistical significance, and others by chance observing
a smaller, non significant effect. This should not by itself be
taken to imply any conflict between studies. Such a bias
affects also the present study: in fact, although this is one of
the larger consecutive series of node negative patients repor-
ted so far (Clark & McGuire, 1991), a c-erbB-2 expression
was observed in a minority of cases showing a limited
number of events, thus allowing for a wide statistical varia-
tion of observed results.
A significant association to prognosis was observed only
for a small subset (8.7%) of cases, showing strong diffuse
immunostaining. This finding may suggest that prognosis is
better predicted by the degree of expression of c-erbB-2.
Although intraobserved repeatibility was high in the present
study, subjective assessment of the degree of staining in
clinical practice remains unreliable. If the degree of expres-
sion is important then objective molecular biological techni-
ques would be required for quantification.
However, the observed association of strong diffuse im-
munostaining with a worse prognosis was not independent of
other prognostic indicators, as shown during multivariate
analysis, and the finding has no clinical relevance, as only
eight out of 67 total recurrences did occur in this subset of
patients.
In conclusion, the findings of the present study, in accor-
dance with other reports (Clark & McGuire, 1991; O'Reilly
et al., 1991; Perren, 1991), suggest that c-erbB-2 expression
has a very limited prognostic value in node negative breast
cancer and cannot be used in current practice to predict the
clinical course of these patients. Larger studies or ultimately
meta-analysis will be required to clearly demonstrate its
prognostic significance.
Table IV Multivariate analysis of the association to disease-free and overall survival. The relative risk of recurrence/death has been set to 1
for reference categories(a)
Relative 95% confidence Chi- P
Variable risk limits square value
Disease-free survival
Tla 1.00
T2 1.72 0.88-3.35 2.59 0.11
T3-4 1.39 1.11-1.42 8.32 0.0039
Gla 1.00
G2 1.32 0.69-2.51 0.73 0.39
G3 1.48 0.92-2.36 2.65 0.10
c-erbB-2 0 1.00
c-erbB-2 1-3 1.02 0.94-1.11 0.35 0.56
c-erbB-2 0-2 1.00
c-erbB-2 3 1.19 0.85-1.17 1.06 0.30
Overall survival
Tla 1.00
T2 2.11 0.98-4.53 3.67 0.055
T3-4 1.51 1.20-1.91 12.04 0.0005 Gla 1.00
G2 1.42 0.70-2.87 0.95 0.33
G3 1.44 0.87-2.38 2.00 0.16
c-erbB-2 0 1.00
c-erbB-2 1-3 1.04 0.96-1.13 0.96 0.33
c-erbB-2 0-2 1.00
c-erbB-2 3 1.12 0.94-1.33 1.73 0.19
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